Figure 1 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma

<jats:p>&lt;p&gt;Characterization of ErlR and AfaR HNSCC cell models. &lt;b&gt;A&lt;/b&gt; and &lt;b&gt;B,&lt;/b&gt; Dose response curves for (&lt;b&gt;A&lt;/b&gt;) Fadu and (&lt;b&gt;B&lt;/b&gt;) Cal27 parental, ErlR, or AfaR cell lines treated with the indicated dose range of afatinib or erlotinib for 72 hours. &lt;b&gt;C,&lt;/b&gt; Representative Western blot images for active RTKs EGFR, MET, and HER2. &lt;b&gt;D,&lt;/b&gt; Quantification of Western blots shown in &lt;b&gt;C&lt;/b&gt;, with values normalized to those in parental cell lines. Graphs display baseline activation relative to total levels of each protein, based on &lt;i&gt;n&lt;/i&gt; = 3. Note that for some proteins analyzed (e.g., MET), there was a significant intensity difference between FaDu and Cal27 models. For these cases, multiple exposures were taken for the relevant data, and quantification was performed based on primary Western blot data within a linear signal range. &lt;b&gt;E,&lt;/b&gt; GSEA comparing Fadu and Cal27 AfaR or ErlR vs. Fadu and Cal27 parental cells, as indicated. RNA-seq analysis shown is averaged from two biological replicates. &lt;b&gt;F&lt;/b&gt; and &lt;b&gt;G,&lt;/b&gt; Representative Western blot images (&lt;b&gt;F&lt;/b&gt;) and quantification (&lt;b&gt;G&lt;/b&gt;) for indicated biomarkers of epithelial identity or EMT, based on &lt;i&gt;n&lt;/i&gt; = 3 biological repeats. Bar graphs display data normalized for each parental cell line. &lt;i&gt;P&lt;/i&gt; values are based on one-way ANOVA followed by Tukey multiple comparison test. *, &lt;i&gt;P&lt;/i&gt; ≤ 0.05; **, &lt;i&gt;P&lt;/i&gt; ≤ 0.001; ****, &lt;i&gt;P&lt;/i&gt; ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates. ES, enrichment score.&lt;/p&gt;</jats:p>